The fold change and expression status of TPD52, KLF9, miR-223, and PKCε for each clinicopathological feature, i.e., low tumor stage groups I–II and advanced tumor stage groups III–IV, distant metastatic vs. non-metastatic group, and treatment status of patients (e.g., chemotherapy, radiotherapy, or chemoradiotherapy), are shown in Table 3. This evidence concerns the gene PRKCE and neoplasm.